Dr. Martens plc Logo

Dr. Martens plc

DOCMF

(2.5)
Stock Price

0,72 USD

11.53% ROA

21.55% ROE

7.16x PER

Market Cap.

550.888.310,65 USD

90.52% DER

5.73% Yield

7.32% NPM

Dr. Martens plc Stock Analysis

Dr. Martens plc Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Dr. Martens plc Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (35.2%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

3 Revenue Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

4 PBV

The stock's PBV ratio (2.88x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

5 Assets Growth

This company's revenue has shown remarkable growth over the past three years, making it an excellent choice for seeking a consistently prosperous investment.

6 Dividend Growth

With a history of consistent dividend increases over the last three years, the company has proven to be a reliable choice for investors seeking reliable income.

7 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (24) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

8 DER

The company has a high debt to equity ratio (112%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

9 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

10 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

11 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

Dr. Martens plc Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Dr. Martens plc Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Sell
4 Stoch RSI Hold

Dr. Martens plc Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Dr. Martens plc Revenue
Year Revenue Growth
2014 163.904.000
2015 235.300.000 30.34%
2016 232.400.000 -1.25%
2017 290.600.000 20.03%
2018 348.600.000 16.64%
2019 454.400.000 23.28%
2020 672.200.000 32.4%
2021 773.000.000 13.04%
2022 908.300.000 14.9%
2023 1.000.300.000 9.2%
2024 1.925.200.000 48.04%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Dr. Martens plc Research and Development Expenses
Year Research and Development Expenses Growth
2014 0
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Dr. Martens plc General and Administrative Expenses
Year General and Administrative Expenses Growth
2014 0
2015 39.600.000 100%
2016 45.000.000 12%
2017 61.100.000 26.35%
2018 145.800.000 58.09%
2019 192.600.000 24.3%
2020 259.000.000 25.64%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Dr. Martens plc EBITDA
Year EBITDA Growth
2014 18.588.000
2015 38.400.000 51.59%
2016 29.200.000 -31.51%
2017 36.700.000 20.44%
2018 46.000.000 20.22%
2019 77.800.000 40.87%
2020 171.200.000 54.56%
2021 225.100.000 23.94%
2022 265.000.000 15.06%
2023 235.000.000 -12.77%
2024 484.400.000 51.49%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Dr. Martens plc Gross Profit
Year Gross Profit Growth
2014 75.904.000
2015 108.700.000 30.17%
2016 112.500.000 3.38%
2017 148.700.000 24.34%
2018 186.000.000 20.05%
2019 260.600.000 28.63%
2020 401.500.000 35.09%
2021 470.500.000 14.67%
2022 578.800.000 18.71%
2023 618.100.000 6.36%
2024 1.143.600.000 45.95%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Dr. Martens plc Net Profit
Year Net Profit Growth
2014 -32.000.000
2015 200.000 16100%
2016 -12.000.000 101.67%
2017 -11.300.000 -6.19%
2018 -5.700.000 -98.25%
2019 17.200.000 133.14%
2020 74.800.000 77.01%
2021 34.700.000 -115.56%
2022 181.200.000 80.85%
2023 128.900.000 -40.57%
2024 200.800.000 35.81%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Dr. Martens plc Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2014 0
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Dr. Martens plc Free Cashflow
Year Free Cashflow Growth
2014 -3.031.999
2015 17.800.000 117.03%
2016 21.500.000 17.21%
2017 27.700.000 22.38%
2018 29.600.000 6.42%
2019 38.900.000 23.91%
2020 99.500.000 60.9%
2021 99.500.000 0%
2022 159.400.000 37.58%
2023 25.900.000 -515.44%
2024 169.600.000 84.73%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Dr. Martens plc Operating Cashflow
Year Operating Cashflow Growth
2014 5.024.000
2015 19.800.000 74.63%
2016 25.800.000 23.26%
2017 34.400.000 25%
2018 46.000.000 25.22%
2019 56.000.000 17.86%
2020 121.400.000 53.87%
2021 121.400.000 0%
2022 184.400.000 34.16%
2023 77.300.000 -138.55%
2024 181.700.000 57.46%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Dr. Martens plc Capital Expenditure
Year Capital Expenditure Growth
2014 8.055.999
2015 2.000.000 -302.8%
2016 4.300.000 53.49%
2017 6.700.000 35.82%
2018 16.400.000 59.15%
2019 17.100.000 4.09%
2020 21.900.000 21.92%
2021 21.900.000 0%
2022 25.000.000 12.4%
2023 51.400.000 51.36%
2024 12.100.000 -324.79%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Dr. Martens plc Equity
Year Equity Growth
2014 1.509.000
2015 800.000 -88.63%
2016 -11.000.000 107.27%
2017 -18.000.000 38.89%
2018 -29.400.000 38.78%
2019 -8.400.000 -250%
2020 70.500.000 111.91%
2021 150.700.000 53.22%
2022 328.200.000 54.08%
2023 404.200.000 18.8%
2024 368.200.000 -9.78%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Dr. Martens plc Assets
Year Assets Growth
2014 341.150.000
2015 363.200.000 6.07%
2016 376.000.000 3.4%
2017 420.200.000 10.52%
2018 445.800.000 5.74%
2019 450.200.000 0.98%
2020 656.500.000 31.42%
2021 652.800.000 -0.57%
2022 859.100.000 24.01%
2023 992.600.000 13.45%
2024 952.400.000 -4.22%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Dr. Martens plc Liabilities
Year Liabilities Growth
2014 339.641.000
2015 362.400.000 6.28%
2016 387.000.000 6.36%
2017 438.200.000 11.68%
2018 475.200.000 7.79%
2019 458.600.000 -3.62%
2020 586.000.000 21.74%
2021 502.100.000 -16.71%
2022 530.900.000 5.42%
2023 588.400.000 9.77%
2024 584.200.000 -0.72%

Dr. Martens plc Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.09
Net Income per Share
0.08
Price to Earning Ratio
7.16x
Price To Sales Ratio
0.51x
POCF Ratio
4.05
PFCF Ratio
5.25
Price to Book Ratio
1.53
EV to Sales
0.85
EV Over EBITDA
4.04
EV to Operating CashFlow
6.53
EV to FreeCashFlow
8.66
Earnings Yield
0.14
FreeCashFlow Yield
0.19
Market Cap
0,55 Bil.
Enterprise Value
0,91 Bil.
Graham Number
0.82
Graham NetNet
-0.3

Income Statement Metrics

Net Income per Share
0.08
Income Quality
1.77
ROE
0.22
Return On Assets
0.08
Return On Capital Employed
0.18
Net Income per EBT
0.74
EBT Per Ebit
0.72
Ebit per Revenue
0.14
Effective Tax Rate
0.26

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.59
Operating Profit Margin
0.14
Pretax Profit Margin
0.1
Net Profit Margin
0.07

Dividends

Dividend Yield
0.06
Dividend Yield %
5.73
Payout Ratio
1.01
Dividend Per Share
0.03

Operating Metrics

Operating Cashflow per Share
0.14
Free CashFlow per Share
0.11
Capex to Operating CashFlow
0.25
Capex to Revenue
0.03
Capex to Depreciation
0.38
Return on Invested Capital
0.16
Return on Tangible Assets
0.12
Days Sales Outstanding
21.46
Days Payables Outstanding
75.68
Days of Inventory on Hand
208.99
Receivables Turnover
17.01
Payables Turnover
4.82
Inventory Turnover
1.75
Capex per Share
0.03

Balance Sheet

Cash per Share
0,11
Book Value per Share
0,37
Tangible Book Value per Share
0.1
Shareholders Equity per Share
0.37
Interest Debt per Share
0.37
Debt to Equity
0.91
Debt to Assets
0.35
Net Debt to EBITDA
1.59
Current Ratio
2.85
Tangible Asset Value
0,10 Bil.
Net Current Asset Value
-0,15 Bil.
Invested Capital
786600000
Working Capital
0,28 Bil.
Intangibles to Total Assets
0.28
Average Receivables
0,10 Bil.
Average Payables
0,11 Bil.
Average Inventory
284550000
Debt to Market Cap
0.61

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Dr. Martens plc Dividends
Year Dividends Growth
2022 0
2023 0 0%
2024 0 0%

Dr. Martens plc Profile

About Dr. Martens plc

Dr. Martens plc designs, develops, procures, markets, sells, and distributes footwear in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. Its product segments include originals, fusion, kids, and casual, as well as accessories. The company offers its products under the Dr. Martens brand name. Dr. Martens plc was founded in 1945 and is based in London, the United Kingdom.

CEO
Mr. Kenneth Wilson
Employee
2.630
Address
28 Jamestown Road
London, NW1 7BY

Dr. Martens plc Executives & BODs

Dr. Martens plc Executives & BODs
# Name Age
1 Graham Calder
Chief Technology Officer
70
2 Ms. Bridget Jolliffe
Chief People Officer
70
3 Mr. Sean O'Neill
Chief Digital Officer
70
4 Ms. Emily Clare Reichwald
Chief Sustainability Officer
70
5 Mr. Giles Wilson
Chief Financial Officer & Director
70
6 Mr. Kenneth Wilson
Chief Executive Officer & Director
70
7 Mr. Onyeije Ogueri Nwokorie
Chief Brand Officer
70
8 Mr. Geert Peeters
Chief Operating Officer
70
9 Mr. Derek Chan
President of APAC
70
10 Mr. Adam M. Meek
Chief Product Officer
70

Dr. Martens plc Competitors